VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds

Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
You are here: IndiaNotes >> Research & Analysis >> IPOs >> Overview

Lauras Labs IPO

Industry: Pharmaceuticals and health care | Prospectus

What Are Analysts Saying?

SPA Securities recommends Laurus Labs IPO for long-term gains
SPA Securities, 06 Dec 2016
Laurus Labs is available at FY18E P/E of 24x which is in discount to high growth pharma stocks. Company is trading at FY17 annualized EV/EBITDA of ~13x which seems attractive. We recommend investors to SUBSCRIBE to the issue for long term gains.

Laurus Labs IPO: Subscribe for long-term gains - Nirmal Bang
Nirmal Bang, 06 Dec 2016
Nirmal Bang likes the business model of the company given its leadership position in the selected therapies, strong growth prospects and improving profitability. At upper price band of Rs 428, the stock looks attractive and hence they recommend investors to subscribe the issue for long term gains.

Laurus Labs IPO: Hem Securities recommend to 'Avoid'
Hem Securities, 06 Dec 2016
At price band of Rs 426-428, p/e multiple will turn out to be 30 on post issue annualized H1FY17 EPS of Rs 14/share of company. Looking at the present valuations of company, issue looks fully priced. Hence due to high valuations of company, Hem Securities recommend \"Avoid\" on issue.

Jainam Wealth recommend 'Avoid' on the Laurus Labs IPO
Jainam Research, 05 Dec 2016
According to Jainam Research, only ARVs, Hepatitis C & Oncology contributed 92% in FY16, while top-5 customers contributed 68% of revenue at Laurus Labs. Besides, the company also has lower profitability margins and higher debt level.

Laurus Labs IPO: Investors with long term view may apply
SMC, 05 Dec 2016
Considering the P/E valuation on the upper end of the price band of Rs. 428, the stock is priced at pre issue P/E of 31.82x on its FY16 EPS of Rs. 13.45. Post issue, the stock is priced at a P/E of 35.11x on its EPS of Rs. 12.19.

Issue Details

Open Date: 06 Dec 16 Min Application Amount: Rs. 14910
Close Date: 08 Dec 16 Min bid (No. of shares): 35
Offer Price: Rs. 426 Issue Size: Rs. 300 Cr
Listing Exchanges: BSE, NSE Issue Size (Shares): 24107440

About the Company

Incorporated in 2005, Laurus Labs Ltd is Hyderabad based pharmaceutical company. Laurus Labs is in the business of manufacturing generic active pharmaceutical ingredients (APIs) for therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. Company also manufacture APIs in oncology and other therapeutic areas.

Objective of the Issue

"Objects of the Issue:

The object of the issue are to:
1. Pre-payment of term loans; and
2. General corporate purposes."